EGI
FBRX icon

EAM Global Investors’s Forte Biosciences FBRX Stock Holding History

EAM Global Investors’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,241
Closed -$1.5M – 144
2020
Q3 		$1.5M Buy
+1,241
New +$823K 0.55% 89

Other funds holding FBRX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

EAM Global Investors's FBRX Position: Q4 2020 in Review

EAM Global Investors sold out of Forte Biosciences (FBRX) in Q4 2020, closing a stake of 1,241 shares — an estimated $1.5M sold.

EAM Global Investors first reported a position in FBRX in Q3 2020 and held it in 1 quarter. The position peaked at $1.5M in Q3 2020. 49 funds tracked by Wall St. Rank hold FBRX as of Q4 2020.

  • EAM Global Investors reported no remaining Forte Biosciences position as of Q4 2020 after selling out during the quarter.
  • EAM Global Investors sold 1,241 Forte Biosciences shares in Q4 2020, an estimated $1.5M.
  • EAM Global Investors first reported a position in Forte Biosciences in Q3 2020 and held it in 1 quarter.
  • EAM Global Investors's Forte Biosciences position peaked at $1.5M in Q3 2020.
  • 49 funds tracked by Wall St. Rank held Forte Biosciences as of Q4 2020.

Based on EAM Global Investors's 13F filing for Q4 2020, filed 11 Feb 2021.